Trevi Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 9, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 9, 2026

TRVI$14.91-2.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Comprehensive Loss

(Amounts in thousands, except share and per share amounts)

	Three Months EndedSeptember 30,		Nine Months EndedSeptember 30,
	2026	2025	2026	2025
Operating expenses:
Research and development	$19,064	$10,085	$44,157	$27,285
General and administrative	5,422	3,831	15,751	11,823
Total operating expenses	24,486	13,916	59,908	39,108
Loss from operations	(24,486)	(13,916)	(59,908)	(39,108)
Other income (expense):
Interest income, net	3,018	2,101	7,409	4,633
Other expense, net	(3)	(2)	(1)	(16)
Total other income, net	3,015	2,099	7,408	4,617
Loss before income taxes	(21,471)	(11,817)	(52,500)	(34,491)
Income tax benefit	(19)	(15)	(59)	(48)
Net loss	$(21,452)	$(11,802)	$(52,441)	$(34,443)
Basic and diluted net loss per common share outstanding	$(0.13)	$(0.08)	$(0.34)	$(0.26)
Weighted average shares of common stock used in net loss per share attributable to common stockholders, basic and diluted	159,727,489	145,104,986	154,025,958	131,122,754
Net loss	$(21,452)	$(11,802)	$(52,441)	$(34,443)
Other comprehensive loss:
Net unrealized (losses) gains on available-for-sale marketable securities	(1,075)	6	(1,648)	(31)
Comprehensive loss	$(22,527)	$(11,796)	$(54,089)	$(34,474)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.